Natural-killer cell activity and cytogenetic response in chronic myelogenous leukemia treated with alpha-interferon.
Meseri
A
A
Delwail
V
V
Mahon
F X
FX
Pelletier
D
D
Guilhot
F
F
Brizard
A
A
Gombert
J
J
Tanzer
J
J
Goube de Laforest
P
P
D000293:Adolescent; D000328:Adult; D000368:Aged; D002675:Child, Preschool; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D007694:Killer Cells, Natural / Q000276:immunology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins